JPRN-UMIN000008955已完成2 期
Randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. - CAPTURE
CAPTURE Clinical Trial Group0 个研究点目标入组 150 人开始时间: 2012年9月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Prior treatment of bevacizumab 2)Allergy to paclitaxel 3)Brain metastasis with risk of bleeding 4)Pregnancy, nursing 5)Active hepatitis 6)Non-healing severe wound or traumatic bone fracture 7)Pleural effusion, ascites or pericardial effusion that requires drainage 8)Uncontrollable hypertension 9)Usage of antithrombotic agents 10)Continuous administration of corticosteroid 11)Symptomatic congestive heart failure, unstable angina, arrhythmia requiring treatment, myocardial infarction within 1 year 12)Idiopathic pulmonary fibrosis or interstitial pneumonitis 13)Symptomatic cerebral vascular disturbance, or its history within 1 year 14)Deep venous thrombosis or pulmonary infarction, or its history within 1 year 15)Perforation of digestive tract, or its history within 1 year 16)Plan of surgery with risk of bleeding Double cancer within 5 years of disease free interval 17)Symptomatic dysfunctional peripheral neuropathy 18)Active peptic ulcer 19)Body temperature more than 38C
研究者
相似试验
进行中（未招募）
不适用
Maintenance therapy in advanced Lung Cancer.Advanced non-small cell lung cancerEUCTR2013-001237-41-NOorwegian University of Science and Technology
进行中（未招募）
不适用
PHASE II STUDY FOR METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFOXIRI AND BEVACIZUMAB AND THEN TREATED WITH BEVACIZUMAB OR WITH BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPYMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006332-23-ITARCO
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem, or other not further classified low malignant lymphoma byimmunohistochemistry.MedDRA version: 14.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023407-95-FRF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A study to compare subcutaneous MabThera (rituximab) maintenance therapy continued until progression with observation in relapsed/refractory NHL patients who have completed and responded to MabThera containing induction/maintenance therapy.Patients with relapsed or refractory CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system, or other not further classified low malignant lymphoma by immunohistochemistry.MedDRA version: 14.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023407-95-ESF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to a 6-month rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem, or other not further classified low malignant lymphoma byimmunohistochemistry.MedDRA version: 14.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023407-95-GRF. Hoffmann-La Roche Ltd700